ライフサイエンスコーパス: serum creatinine

1 eGFR) (ml/min/1.73 m(2)) was calculated from serum creatinine.

2 d to INCPH, history of ascites, or increased serum creatinine.

3 than 15 mL/min per 1.73 m(2), or doubling of serum creatinine.

4 levated at earlier time points compared with serum creatinine.

5 ization for heart failure, ESRD, or doubling serum creatinine.

6 e depletion, proteinuria, and an increase in serum creatinine.

7 in estimated glomerular filtration rate from serum creatinine, 0.01 g/dl (95% CI 0.0004-0.02; p < 0.0

8 Neurological and renal impairments (serum creatinine, 0.87+/-0.20; median, 0.80; interquarti

9 raft function 3 years posttransplant (median serum creatinine 1.5 mg/dL).

10 tter function at 24 months postindex biopsy (serum creatinine 1.75 mg/dl, geometric mean, vs class 2:

11 throughout the follow-up (36 months post KT: serum creatinine, 1.18 mg/dL).

12 ocrit (1.83 [1.21-2.77] per 5% increase) and serum creatinine (10.82 [1.49-78.69] per 1 mg/dL increas

13 g/hr), 2) mild-moderate acute kidney injury (serum creatinine 132-354 umol/L or minimum urine output

14 liver disease era (68% vs. 82%; P = 0.0001), serum creatinine (2.9+/-1.9 vs. 4.3+/-2.5; P < 0.0001),

15 covery compared with HAMP and SCS (mean peak serum creatinine: 3.66 +/- 1.33 mg/dL [postoperative d 1

16 Primary endpoint was change of serum creatinine 48 h after PCI (Deltacreatinine).

17 2 weeks after transplantation predicted the serum creatinine 6 months and the estimated creatinine c

18 ration of less than 0.97 mmol/L (3.0 mg/dL); serum creatinine 8.8-35.4 mumol/L (0.1-0.4 mg/dL); radio

19 ney (SLK) transplant allocation was based on serum creatinine, a metric that disadvantaged women rela

20 or acute kidney injury based on the level of serum creatinine above the upper limit of reference inte

21 Daily peak serum creatinine (adjusted for baseline) values were als

22 1.7% for >/=30% decline in eGFR, doubling of serum creatinine, AKI, and kidney failure, respectively.

23 uated multiple organ injury as determined by serum creatinine, alanine aminotransferase, lactate dehy

24 and Ki-67 and measuring mucosal ulcer area, serum creatinine, ALT, and body weight at day 4.

25 23% of variation in recorded 6-month serum creatinine among obese donors was attributed to ce

26 achieved SVR12 experienced an improvement in serum creatinine and a reduction in proteinuria.

27 Limitation: Serum creatinine and albuminuria were measured only once

28 ) mice were resistant to AKI, with decreased serum creatinine and ameliorated histologic changes comp

29 lower baseline values for viral load and for serum creatinine and aminotransferase levels each correl

30 , animals transplanted with NEVKP grafts had serum creatinine and blood urea nitrogen values comparab

31 ed with SCS grafts had persistently elevated serum creatinine and blood urea nitrogen when compared w

32 n stage 3 acute kidney injury and daily peak serum creatinine and both delirium and coma.

33 en 2008 and 2011, had available preadmission serum creatinine and BP measures, and were not known to

34 e Prognosis Consortium (CKD-PC) with data on serum creatinine and change in albuminuria and more than

35 Ps (rs3811321 and rs6565887) associated with serum creatinine and clinical outcome.

36 in glomerular filtration rate estimated from serum creatinine and cystatin C (eGFR) from baseline to

37 ated glomerular filtration rate (eGFR) using serum creatinine and cystatin C concentrations, and micr

38 inally, by functional markers of filtration (serum creatinine and cystatin C).

39 d glomerular filtration rate (eGFR) based on serum creatinine and cystatin C.

40 of aliskiren on renal outcomes (doubling of serum creatinine and end-stage renal disease) when used

41 rox and had available baseline and follow-up serum creatinine and ferritin measurements.

42 tors of clinical responder status were lower serum creatinine and KCCQ-OS scores and treatment assign

43 uction in neutrophil levels and increases in serum creatinine and low-density lipoprotein cholesterol

44 Patients with outpatient serum creatinine and potassium tests in the 30 days afte

45 y patients at risk of having abnormally high serum creatinine and potassium values in follow-up.

46 gnificantly decreased ectopic calcification, serum creatinine and serum phosphorus levels, circulatin

47 To evaluate guideline-concordant testing for serum creatinine and serum potassium within 180 days bef

48 ing the difference between baseline and peak serum creatinine and staged according to Kidney Disease

49 d 24 h after reperfusion for renal function (serum creatinine and urea), complement deposition (C3b/c

50 ose-dependent manner, significantly reducing serum creatinine and urea, tubular injury, neutrophil an

51 died 1,243 patients and classified AKI using serum creatinine and urine output.

52 all three populations, AKI was defined using serum creatinine and urine output.

53 ed criteria of acute kidney injury, that is, serum creatinine and urine production, are not useful as

54 donors (111 had AKI, defined as doubling of serum creatinine) and ascertained outcomes in the corres

55 lues (hemoglobin A(1c), blood urea nitrogen, serum creatinine), and socioeconomic factors (health ins

56 risks of >/=30% decline in eGFR, doubling of serum creatinine, and AKI; however, apixaban did not hav

57 end-stage renal disease [ESRD], doubling of serum creatinine, and all-cause mortality-singly and as

58 delayed graft function, primary nonfunction, serum creatinine, and biliary complications.

59 ata, including admission, peak, and terminal serum creatinine, and biopsy data when available to diff

60 reduced proteinuria, glomerular thrombosis, serum creatinine, and glomerular macrophage infiltration

61 gher oxygen extraction, a lower decrement of serum creatinine, and higher levels of NGAL and ET-1 wer

62 developed septic shock, oliguria, increased serum creatinine, and reduced creatinine clearance (AKI)

63 Stage 1 urine output, serum creatinine, and urinary [TIMP-2]*[IGFBP7] greater

64 In Raynaud phenomenon, male sex, age, and serum creatinine are related to mortality.

65 This is partly because the use of serum creatinine as the comparator has several limitatio

66 or characteristics were compared by recorded serum creatinine at 6 months postdonation, and multileve

67 Elevated serum creatinine at the time of heart transplant is an i

68 DC-GS remained significant when adjusted for serum creatinine at the time of the biopsy, Banff i, ci

69 0.0001) as well as smaller mean increases in serum creatinine at week 48 (0.01 mg/dL [0.00-0.02] vs 0

70 in patients with diabetes and CKD from using serum creatinine-based thresholds to using eGFR-based th

71 All parameters of renal function (serum creatinine, blood urea nitrogen, and electrolytes)

72 sed renal function, as indicated by elevated serum creatinine, BUN, and potassium.

73 injury (sub-AKI) refers to patients with low serum creatinine but elevated alternative biomarkers of

74 In contrast with serum creatinine, C-mannosyltryptophan and pseudouridine

75 Two metrics, a rise in serum creatinine concentration and a decrease in urine o

76 However, mean serum creatinine concentration and albuminuria remained

77 lt intake, ES rats still showed a lower mean serum creatinine concentration and less albuminuria, as

78 group (RR, 1.61 [0.86 to 3.01]; P = .15) and serum creatinine concentration increased by a median of

79 ienced AKI defined using observed changes in serum creatinine concentration measured during hospitali

80 iltration rate, manifested by an increase in serum creatinine concentration or oliguria, and classifi

81 Current expressions based on serum creatinine concentration overestimate kidney funct

82 AKI was defined as rise in serum creatinine concentration to 1.5-fold above baselin

83 Mean serum creatinine concentration was 2.93 +/- 0.89 mg/dl a

84 njury defined as an increase of 0.3 mg/dL in serum creatinine concentration within 48 hours of surger

85 However, serum creatinine concentration, albuminuria, and glomeru

86 nal hazard model adjusted for age, diabetes, serum creatinine concentration, urinary albumin concentr

87 and vAKI that induced a similar increase in serum creatinine concentration.

88 performance to predict outcome compared with serum creatinine concentration.

89 POL1 2-renal-risk-variant kidneys, follow-up serum creatinine concentrations were higher than that in

90 e obtained data on age, sex, height, weight, serum creatinine concentrations, and results for GFR fro

91 function [DGF] before day 90) were recorded; serum creatinine (Cr) at day 90 was defined as baseline.

92 ing or computed tomography (CT) and for whom serum creatinine (Cr) levels were obtained within 72 hou

93 ing Kidney Disease/Improving Global Outcomes serum creatinine criteria.

94 We used serum creatinine criterion of KDIGO definition for diagn

95 s from UK Biobank, eGFR was calculated using serum creatinine, cystatin C (eGFRcys) and creatinine-cy

96 jury (AKI) is defined by a rapid increase in serum creatinine, decrease in urine output, or both.

97 At 24 hours after reperfusion, serum creatinine decreased in postcond-CsA and IPC compa

98 Serum creatinine decreased more (by 0.17 mg/dL [95% CI,

99 dneys transplanted from deceased donors with serum creatinine-defined acute kidney injury (AKI) have

100 We examined if serum creatinine-defined donor AKI modified this associa

101 of histopathologic findings, with increased serum creatinine detected only in the ReninAAV-treated d

102 donor and recipient age and sex, ethnicity, serum creatinine, diabetes mellitus, and heart failure c

103 e end points (albuminuria and a composite of serum creatinine doubling or 40% estimated glomerular fi

104 t did produce a mild, reversible increase in serum creatinine (effect size vs placebo: increase of 4.

105 Clinical AKI, measured by serum creatinine elevation, is associated with long-term

106 ITUDE was defined as a sustained doubling of serum creatinine, end-stage renal disease, or renal deat

107 orsening chronic kidney disease, doubling of serum creatinine, end-stage renal disease, renal transpl

108 sity lipid, HbA1c (glycosylated hemoglobin), serum creatinine, eosinophils, lymphocyte, monocytes, ne

109 tic syndrome; and a composite of doubling of serum creatinine, ESRD, or death between 100 Rtx-treated

110 ratio >30 mg/g), and chronic kidney disease (serum creatinine estimated glomerular filtration rate [e

111 gnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate,

112 ted hemoglobin (HbA1c), blood urea nitrogen, serum creatinine, estimated glomerular filtration rate,

113 s variation in recorded 6-month postdonation serum creatinine exists among obese living donors, with

114 While serum creatinine fell at 12 hours, serum cystatin C incr

115 finition of >=0.5 mg/dL or >=25% increase in serum creatinine from baseline within 48 hours), and AKI

116 3 mg/dL within 48 hours or >=50% increase in serum creatinine from baseline within 7 days and the his

117 , and on the clinical end point (doubling of serum creatinine, GFR<15 ml/min per 1.73 m(2), or ESKD)

118 filtration rate in patients with stabilized serum creatinine (grade A).

119 mL/kg/hr), or 3) severe acute kidney injury (serum creatinine > 354 umol/L or renal replacement thera

120 repeats), and defined AKI as an increase in serum creatinine >/=0.3 mg/dl within 48 hours or >/=50%

121 rtality, use of RRT, and persistent elevated serum creatinine >/=200% from baseline at hospital disch

122 mal) or a renal safety event (an increase in serum creatinine >1.5 times the baseline value or a new

123 ve risk of death was higher in patients with serum creatinine >= 100 mumol/L at surgery (33% versus 0

124 ns related to INCPH, history of ascites, and serum creatinine >= 100 mumol/L: 5% of the patients with

125 n episode of AKI (i.e., peak/nadir inpatient serum creatinine >=1.5).

126 SD, 0.14-0.98; P = 0.04), and high baseline serum creatinine (hazard ratio, 4.12; SD, 1.7-10.3; P =

127 ysfunctional grafts with an elevation in the serum creatinine; however, our group and others found th

128 EPI eGFR (HR 1.5, p = 0.001) and doubling of serum creatinine (HR 2.0, p < 0.001).

129 [CI]: 0.66 to 0.89; p < 0.001), doubling of serum creatinine (HR: 0.62; 95% CI: 0.40 to 0.95; p = 0.

130 improved by 12% and 7.4%, respectively, and serum creatinine improved by 27%.

131 metformin protected against AKI, with lower serum creatinine, improved histological changes and decr

132 The elevated level of serum creatinine in CNI groups was abolished by Aliskire

133 However, we noted significant improvement in serum creatinine in the hypomorphs at 3 and 10 days afte

134 m except for an increased additional rise in serum creatinine in the plazomicin arm compared with the

135 d acute kidney injury (CI-AKI), defined as a serum creatinine increase >/=0.5 mg/dL or >/=25% within

136 ation with acute kidney injury (defined by a serum creatinine increase during hospitalization > 0.3 m

137 respecified secondary analysis compared AKI (serum creatinine increase of >= 25% or 0.5 mg/dL after 1

138 e, 3 events-syncope, pulmonary embolism, and serum creatinine increase-in 3 patients were determined

139 Serum creatinine increased from 1.7+/-0.4 mg/dL at 3 mon

140 Persistent congestion trumps serum creatinine increases in predicting adverse heart f

141 Serum creatinine is not a direct indicator of renal inju

142 e secondary MR in the COAPT trial were lower serum creatinine, KCCQ-OS score and MitraClip treatment.

143 A6 in a model of muscular dystrophy reduced serum creatinine kinase, a biomarker of disease.

144 An increase in serum creatinine led to the addition of sirolimus at 3 m

145 ared with WT animals, demonstrating improved serum creatinine, less histologic damage, reduced proinf

146 calciphylaxis without severe kidney disease (serum creatinine level >3 mg/dL; glomerular filtration r

147 similar, including median age (68 years) and serum creatinine level (305.5 and 273.5 umol/L in BD and

148 005), as well as higher risks of an elevated serum creatinine level (4.1% vs. 2.7%, P=0.009) and an e

149 a significantly elevated risk of doubling of serum creatinine level (HR, 1.53; 95% CI, 1.42 to 1.65),

150 placebo, reduced risk of acute elevation in serum creatinine level (pooled relative risk, 0.57; 95%

151 lacebo, increased risk of acute elevation in serum creatinine level (pooled relative risk, 1.52; 95%

152 Median baseline serum creatinine level (range) was 1.4 (0.8-2.4) mg/dl,

153 s that altered risk for an acute increase in serum creatinine level and had reported between-group di

154 t-term effects of interventions on change in serum creatinine level and more meaningful clinical outc

155 ase in albumin-to-creatinine ratio (ACR) and serum creatinine level and more severe renal lesions.

156 ups, as soon as day 12 with no difference in serum creatinine level and proteinuria at 1, 3, 6, and 1

157 value of using small to moderate changes in serum creatinine level as end points in clinical trials.

158 Normal systolic BP and serum creatinine level at 1 year after treatment were as

159 ncrease of at least 50% from baseline in the serum creatinine level at 90 days.

160 g KDIGO criteria and was based on changes in serum creatinine level from hospital days 0 to 2 through

161 ld to moderate, often temporary elevation in serum creatinine level in placebo-controlled randomized

162 Doubling of the serum creatinine level occurred in 70 of 4645 patients (

163 % women per cohort) had a mean (SD) baseline serum creatinine level of 1.0 (0.2) mg/dL and more than

164 ) (normal level, <142 U/L [2.37 mukat/L]), a serum creatinine level of 93 mumol/L (reference range, 7

165 enal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04)

166 as discharged 6 days posttransplant, and the serum creatinine level was 160 mumol/L (1.8 mg/dL) at 2

167 ound that GFR was significantly greater, and serum creatinine level was significantly lower in TRPC6

168 tine laboratory tests (complete blood count, serum creatinine level), urine albumin/creatinine ratio

169 ular filtration rate (eGFR), doubling of the serum creatinine level, acute kidney injury (AKI), and k

170 orated STAT activity and resulted in reduced serum creatinine level, albuminuria, and renal histologi

171 ates, including acute rejection, doubling of serum creatinine level, and eGFR at year 1 or year 2.

172 ect on estimated glomerular filtration rate, serum creatinine level, and the risk for hemodialysis an

173 , in addition to biochemical indices such as serum creatinine level, are promising biomarkers to trac

174 In adjusted analysis, higher serum creatinine level, black race, older age, and ische

175 macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or deat

176 ression to macroalbuminuria, doubling of the serum creatinine level, initiation of renal-replacement

177 per minute per 1.73 m(2)), a doubling of the serum creatinine level, or death from renal or cardiovas

178 ansgenic mice also significantly ameliorated serum creatinine level, proteinuria, tubular injury, and

179 Thus, the outcome of acute change in serum creatinine level, regardless of underlying biology

180 roposed a new predictive model that combines serum creatinine levels and maximum liver function capac

181 The serum creatinine levels at 3 months were 1.2 mg/dl in th

182 tabases to estimate gestational age-specific serum creatinine levels before, during, and after pregna

183 l and statistically significant decreases in serum creatinine levels compared with levels in animals

184 d antidonor skin graft responses, and normal serum creatinine levels despite withdrawal of all medica

185 Serum creatinine levels from baseline and within day 5 o

186 Serum creatinine levels increased above 150% of baseline

187 Younger age and higher proteinuria and serum creatinine levels increased the likelihood that th

188 Because race and sex affect serum creatinine levels independently of GFR, the earlie

189 Increases in serum creatinine levels of 0.5 mg or more per deciliter

190 s with underlying kidney disease or abnormal serum creatinine levels on hospital days 0 to 2 were amo

191 Drifting of serum creatinine levels over time should also be taken i

192 Serum creatinine levels remained stable throughout the t

193 e (connexin 43+/-) had proteinuria, BUN, and serum creatinine levels significantly lower than those o

194 Serum creatinine levels tended to mildly increase (3% be

195 injury, reduced neutrophil infiltration, and serum creatinine levels were apparent.

196 Serum creatinine levels were measured weekly to monitor

197 s were associated with low tumor grade, high serum creatinine levels, and concomitant diabetes.

198 Peripheral mononuclear cells, serum creatinine levels, and renal biopsies were collect

199 i-alphavbeta5 antibody significantly reduced serum creatinine levels, diminished renal damage detecte

200 Increased serum creatinine levels, high serum titers of donor-spec

201 ficant reductions in cystic disease, BUN and serum creatinine levels.

202 eters: presentation at time of index biopsy, serum creatinine levels/renal function over 24 months of

203 Patients with C-TCMR had higher mean serum creatinine, lower mean estimated glomerular filtra

204 rine output into: 1) no acute kidney injury (serum creatinine < 132 umol/L or urine output >= 0.5 mL/

205 n function (serum bilirubin </=3.0 mg/dL and serum creatinine </=3.0 mg/dL, unless higher concentrati

206 rcumference >94 (males) or >80 (females) cm, serum creatinine <1.2 mg/dL, and normoalbuminuria were r

207 nely screen or monitor bone mineral density, serum creatinine, magnesium, or vitamin B12.

208 Decreased urine output and/or increased serum creatinine may herald the development of acute kid

209 and control groups had similar prepregnancy serum creatinine measurements (0.70+/-0.20 versus 0.69+/

210 hospitalized participants, we used inpatient serum creatinine measurements obtained as part of clinic

211 determine this, we estimated GFR (eGFR) from serum creatinine measurements obtained from 15,612 patie

212 ology Collaboration equation from calibrated serum creatinine measurements.

213 al disease measured by area under the curve (serum creatinine, mg mo/dL) were compared.

214 ned as an absolute or a relative increase in serum creatinine of >0.3 mg/dl or >=50%, respectively, o

215 AKI, defined as a postoperative increase in serum creatinine of >=0.3 mg/dl within 48 hours of surge

216 y outcome was AKI, defined as an increase in serum creatinine of >=0.5 mg/L or a 50% increase from ba

217 The 4 grafts have done well, with an average serum creatinine of 1.45 mg/dL at 2 years (range 1.01-1.

218 the patient has stable renal function with a serum creatinine of 1.6 mg/dL.

219 esented with declining kidney function and a serum creatinine of 2.7 mg/dL.

220 afts preserved with NEVKP demonstrated lower serum creatinine on days 1 to 7 (P < 0.05) and lower pea

221 erence in incidence rates for an increase in serum creatinine or a new requirement for renal replacem

222 lacement therapy or changes in urine output, serum creatinine or both) or death.

223 stage 1 acute kidney injury by urine output, serum creatinine or both, with risk increasing with each

224 he neonatal intensive care unit; doubling of serum creatinine or increase in CKD stage.

225 iated AKI, defined as a >=2-fold increase in serum creatinine or new dialysis requirement directly at

226 Variability of serum creatinine or other definitions of variability sho

227 utweigh any modest or transient increases in serum creatinine or tubular injury markers that occur du

228 over donor kidney injury, measured by either serum creatinine or urine injury biomarkers.

229 Patients were categorized based on worst serum creatinine or urine output into: 1) no acute kidne

230 ge 1 (OR = 3.4), serum bilirubin (OR = 4.4), serum creatinine (OR = 5.4), and cumulative pre-stage 1

231 Serum creatinine (P = 0.005), ascites as indication for

232 NEVKP versus SCS grafts demonstrated similar serum creatinine peak levels (NEVKP, 2.0 +/- 0.5 vs SCS

233 Serum creatinine peaked late (24 hr), when clinical reco

234 serum cystatin C (Pnoninferiority < 0.0001), serum creatinine (Pnoninferiority = 0.0004), and measure

235 imary outcome was AKI defined as the rise in serum creatinine post procedure >/=0.5 mg/dL or >/=25% a

236 uating CKD-progression (higher GFR and lower serum creatinine, proteinuria, kidney inflammatory infil

237 ted risks, while the risk score for abnormal serum creatinine provided moderate discrimination (AUC,

238 ute kidney injury defined as a postoperative serum creatinine rise from preoperative baseline by 50%

239 fined using a standardized definition -i.e., serum creatinine rise of >/=0.3 mg/dL (26.5 mcmol/L) or

240 ute kidney injury according to thresholds of serum creatinine rise.

241 ute kidney injury according to thresholds of serum creatinine rise.

242 ccurred if, within 48 hours postoperatively, serum creatinine rose by 50% or by 0.3 mg/dL (26.5 mumol

243 When serum creatinine (SC) and UO criteria were used, 604 pat

244 kidney injury (AKI) is defined by changes in serum creatinine (SCr) and diuresis with risk/injury/fai

245 Complete response was defined by decrease of serum creatinine (sCr) from baseline to a final value </

246 d glomerular filtration rate (eGFR) based on serum creatinine (sCr) improves early after left ventric

247 Renal Disease (MDRD) performance to predict serum creatinine (SCr) in severe trauma population and d

248 /=25 years with type 1 or type 2 diabetes, a serum creatinine (SCr) level of 1.3-3.3 mg/dl for women

249 --defined as an increase in maximal observed serum creatinine (SCr) level of either (a) >/=0.5 mg/dL

250 er with stable kidney function and available serum creatinine (SCr) measurement before and after imag

251 To assess the association between low serum creatinine (SCr) value at admission and the risk o

252 Replacing serum creatinine (SCr) with estimated glomerular filtrat

253 review on GL and graft function, measured by serum creatinine (SCr), after pregnancy in KT recipients

254 values were correlated with changes in eGFR, serum creatinine (SCr), systolic blood pressure (SBP), r

255 CKD-EPI) equation for adults are recommended serum creatinine (SCr)-based calculations for estimating

256 etween acute tubular injury and elevation in serum creatinine (SCr).

257 >0.5 mg/dl) or a relative (>25%) increase in serum creatinine (sCr).

258 confirmed HRS reversal (CHRSR, defined as 2 serum creatinine [SCr] values </=1.5 mg/dL, at least 40

259 Over half (56.2%) presented with elevated serum creatinine suggestive of acute kidney injury.

260 mary endpoint was a composite of doubling of serum creatinine (sustained for >=30 days) or end-stage

261 sting in these participants and confirmatory serum creatinine testing in phase 1 participants.

262 we enrolled 222 new participants, performing serum creatinine testing in these participants and confi

263 bilistic model optimized for nonlinearity of serum creatinine time series that calculates the risk fu

264 Using Pearson's correlation coefficient, serum creatinine-to-serum cystatin C ratio was found to

265 mide pulses or in case of return to baseline serum creatinine together with reduction of donor-specif

266 predictor: day from ICU admission, age, sex, serum creatinine, trauma, and cardiac surgery.

267 functional status was analyzed by levels of serum creatinine, urea, cystatin-C, and urea creatinine.

268 1000597 was associated with higher levels of serum creatinine, uric acid, calcium and lower urine pH

269 mptoms, including prostate-specific antigen, serum creatinine, urine cytology, imaging, cystourethros

270 Outcome measures included serum creatinine, urine microprotenuira, and immunohisto

271 models that included age, sex, and discharge serum creatinine value alone (integrated discrimination

272 values were more likely to have an abnormal serum creatinine value at baseline if they were non-Hisp

273 severity of acute kidney injury, and higher serum creatinine value at discharge.

274 come: older age, female sex, higher baseline serum creatinine value, albuminuria, greater severity of

275 For each case, serum creatinine values before and after the MRI were co

276 Serum creatinine values ranged from 40 to 446 umol/L.

277 Serum creatinine values within 180 days or less of each

278 on the diagnosis of the index admission and serum creatinine values: 1) acute kidney injury, 2) pneu

279 Baseline serum creatinine was >/=110 mumol/l in 48% of patients i

280 Patients were excluded if their baseline serum creatinine was >1.2mg/dL or they were receiving re

281 Median baseline serum creatinine was 0.97 mg/dL (range 0.7-2.47).

282 Median serum creatinine was 1.8 mg/dL and 0.8 mg/dL in patients

283 The last median serum creatinine was 128.2 +/- 40.8 mumol/L.

284 HIV testing was done monthly and serum creatinine was assessed every 3 months.

285 Serum creatinine was lower in TLR4 allografts at day 14

286 Serum creatinine was measured at each visit, and eGFR wa

287 Serum creatinine was measured.

288 tes after onset of therapy-induced increased serum creatinine was not superior to standard care and r

289 The impact of serum creatinine was restricted to patients with pre-LT

290 Any increase in serum creatinine was seen in 697 (36.1%) and acute kidne

291 At week 48, mean change in serum creatinine was small in both groups (tenofovir ala

292 Posttransplant serum creatinine) was compared among these cohorts.

293 systolic BP target with repeated measures of serum creatinine, we evaluated differences by study arm

294 In both sexes, patients' age and serum creatinine were associated with mortality.

295 imated glomerular filtration rate (eGFR) and serum creatinine were noted.

296 ey disease (CKD) monitoring in primary care, serum creatinine with estimated glomerular filtration ra

297 Long-term graft survival and serum creatinine with kidneys from SpK donors >10 kg wer

298 cline in class 2 at 24 months postdiagnosis; serum creatinine with persistence: 2.48 mg/dL vs 1.65 wi

299 ined AKI as a 0.3 mg/dl absolute increase in serum creatinine within 48 hours, or >=1.5-fold relative

300 There was a transient rise in his serum creatinine without change in urine output; dialysi